Pharma giant GSK announces major restructuring drive to cut 400m in costs


GlaxoSmithKline has announced a major restructuring programme that will see the company slash 400 million in annual costs in an effort to bolster research spending. The pharmaceuticals giant, which has plants at Irvine in Ayrshire and Montrose, said on Wednesday that the savings would be delivered primarily through "supply chain optimisation" and a cut in administrative costs.



from Biotech News